← Back to Search

JAK Inhibitor

Navtemadlin + Ruxolitinib for Myelofibrosis (POIESIS Trial)

Phase 3
Recruiting
Research Sponsored by Kartos Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Confirmed diagnosis of PMF, post-PV MF, or post-ET MF according to WHO criteria
JAK-inhibitor treatment naive
Must not have
Prior Splenectomy
Splenic irradiation within 3 months prior to the first dose
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 years
Awards & highlights

Summary

"This trial is testing if adding navtemadlin to ruxolitinib treatment will be more helpful than using ruxolitinib alone for patients with Myelofibrosis who don't

Who is the study for?
This trial is for patients with Myelofibrosis who haven't had a good enough response to Ruxolitinib. Participants should be new to JAK inhibitor treatments and meet specific health criteria not detailed here.
What is being tested?
The study tests if adding Navtemadlin to Ruxolitinib offers more benefits than Ruxolitinib alone in Myelofibrosis patients with poor responses. It's randomized and blinded, meaning treatment assignments are by chance and unknown to participants and researchers.
What are the potential side effects?
Possible side effects of Navtemadlin may include gastrointestinal symptoms, fatigue, liver issues, or muscle-related problems. Side effects from Ruxolitinib can range from anemia and low blood platelets to dizziness and headache.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a form of myelofibrosis according to WHO standards.
Select...
I have never been treated with JAK inhibitors.
Select...
My myelofibrosis is TP53 wild-type.
Select...
I am currently on a stable dose of ruxolitinib.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had my spleen removed.
Select...
I have not had splenic irradiation in the last 3 months.
Select...
I have previously received treatments targeting specific cancer pathways or p53.
Select...
I am eligible for a bone marrow transplant.
Select...
My white blood cell count more than doubled and exceeded 50 × 10^9/L during ruxolitinib treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2
To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2
Secondary study objectives
To compare overall survival (OS) between Arm 1 and Arm 2
To compare time to progression between Arm 1 and Arm 2

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1Experimental Treatment2 Interventions
Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Group II: Arm 2Active Control2 Interventions
Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib
2018
Completed Phase 3
~1140

Find a Location

Who is running the clinical trial?

Kartos Therapeutics, Inc.Lead Sponsor
16 Previous Clinical Trials
1,450 Total Patients Enrolled
~400 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top